grade
pharmaceutical primary standard
API family
ursodeoxycholic acid
manufacturer/tradename
EDQM
mp
203-204 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
InChI key
RUDATBOHQWOJDD-UZVSRGJWSA-N
Gene Information
human ... NR1H4(9971)
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
Keith Lindor
The New England journal of medicine, 357(15), 1524-1529 (2007-10-12)
R A Rubin et al.
Annals of internal medicine, 121(3), 207-218 (1994-08-01)
To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Personal databases of the authors and MEDLINE were
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001163 | 04061833806388 |